Qiming Venture Partners

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Umoja Biopharma specializes in innovative immunotherapy aimed at transforming cancer treatment and enhancing patient quality of life. The company focuses on reprogramming T cells within the patient's body to effectively target cancer, including solid tumors and hematological cancers that often have poor responses to conventional therapies. Its proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens tailored to various stages of cancer, enabling medical practitioners to directly and safely attack cancer cells. By harnessing the body's immune response, Umoja Biopharma seeks to improve overall patient outcomes and provide more effective treatment options for those affected by cancer.

Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.

Hope Medicine is committed to researching, developing and commercializing the first innovative drugs aimed at improving the quality of life for a wide range of popular male and female diseases.

Epigenic Therapeutics is a biotech firm that offers gene editing therapy.

CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.

Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

GenEditBio is a biotechnology company that focuses on developing gene editing drugs to address unmet medical needs associated with genetic diseases. The company specializes in innovative research and the advancement of in vivo gene editing tools, along with related delivery systems. By providing curative solutions, GenEditBio aims to improve treatment options for patients suffering from genetic disorders.

CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

Hope Medicine is committed to researching, developing and commercializing the first innovative drugs aimed at improving the quality of life for a wide range of popular male and female diseases.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Silicon Yi Technology is a biotech firm specializing in RNA nanopesticide research and development designed to target pests and diseases.

Magair Chemical is a chemical synthesis CRO that was founded by Magera Technology. It is committed to using automated and intelligent platforms to provide new drug R&D customers with a new generation of chemical synthesis CRO services, significantly shortening the delivery of chemical synthesis links in the new drug R&D cycle, and significantly reducing the costs associated with chemical synthesis, removing pharmaceutical synthesis's current reliance on manual operations.

PRCXI Biotechnology is a biotech company that provides bioinformatics and automation solutions for life science and the manufacturing of analytical instruments.

ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.

Yanyin Technology provides AI solutions and scientific research collaboration platforms for biomedical field.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Tachem is a biotechnology company that specializes in the research, development, production, and distribution of products from the protected amino acid series.

Wecare Probiotics is a national high-tech enterprise specializing in the R & D, production, and application of probiotic strains.

Tourmaline Bio is a late-stage clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients with immune diseases. Its primary product candidate, TOUR006, is a fully human monoclonal antibody that targets interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The company leverages over twenty years of clinical and commercial experience associated with the anti-IL-6 and anti-IL-6 receptor antibody class, which has effectively treated over a million patients suffering from a range of autoimmune conditions. Tourmaline Bio is committed to addressing the needs of individuals with life-altering immune diseases through its innovative therapeutic approaches.

JIIOV Technology is a biometric recognition solutions provider.

CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.

Epigenic Therapeutics is a biotech firm that offers gene editing therapy.

Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.

AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals with degenerative ocular diseases. The company's innovative platform focuses on creating treatments that can be delivered directly to the eye, eliminating the need for systemic administration. This targeted approach enhances the potential for effective intervention, allowing healthcare providers to significantly improve the quality of life for patients suffering from various eye conditions. Through its commitment to advancing vision-restoring technologies, Tenpoint Therapeutics is positioned to make a meaningful impact in the field of ocular health.

Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.

LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.

Ailomics Therapeutics, founded in 2022 and headquartered in Shanghai, China, is dedicated to developing innovative drugs for the treatment of immune diseases and tumors. The company utilizes a computational biology platform to analyze multi-omics data from patients, which aids in discovering novel drug mechanisms and targets that contribute to disease progression. Through this approach, Ailomics aims to enhance the understanding of complex diseases and advance the development of effective therapeutic solutions.

CuroVax researches and focuses on developing and producing vaccines for various diseases. It provides biotechnology and microbiology services to improve the health and medical industry. CuroVax was founded in 2011 and is based in Changzhou City, China.

Satellos Bioscience is a private regenerative medicine company dedicated to developing innovative therapeutics aimed at stimulating or restoring muscle regeneration, particularly in severe disorders. The company's primary focus is on creating an oral therapeutic drug for Duchenne muscular dystrophy, targeting the dysregulation that is recognized as a fundamental cause of the disease's progressive characteristics. Through its research and development efforts, Satellos aims to address significant unmet medical needs within the field of muscle-related conditions.

Complete Omics is a developer focused on multi-omics diagnostics aimed at the early detection of diseases, particularly cancer. The company specializes in personalized diagnosis and treatment, leveraging patented technologies across various omics fields. By offering precision companion diagnostics, Complete Omics enables researchers and pharmaceutical companies to conduct highly sensitive and specific health surveillance tests, facilitating improved patient outcomes through tailored medical interventions.

Joes Future Food engages the development, production, testing, and sales of raw and auxiliary materials for food and biological products.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

Caidya is a clinical research organization based in North Carolina, founded in 2021. It specializes in providing personalized solutions across various therapeutic areas and aims to enhance the efficiency of clinical trials. Caidya develops a proprietary technology platform that integrates data from multiple systems, offering a near real-time overview of clinical trials. The organization also offers advisory services focused on clinical development plans, regulatory strategies, and approval processes, which support bio-pharmaceutical and medical companies in optimizing their clinical development capabilities. By facilitating the globalization of innovative drugs, Caidya seeks to accelerate the development of medicines and improve the overall success rates of clinical trials.

OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.

Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.

Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Reunion Biotech focuses on the research and development and industrial transformation of medical hydrogels. The company is committed to becoming an international leading hydrogel technology platform. The current pipeline includes systemic solutions for tumor radiotherapy protection, wound repair, tumor embolization, and drug delivery.

BayOmics is a biotechnology company specializing in the commercial development of proteomics research. It focuses on the application of advanced biological and pharmaceutical technologies aimed at addressing critical illnesses. Utilizing integrated automated proteomics technology, BayOmics conducts functional proteome analyses and engages in the discovery of new drug targets. The company also supports targeted drug research and development based on micro-clinical samples. Through these efforts, BayOmics provides essential technical support to the medical industry, contributing to the advancement of treatments for cancer and other significant diseases.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Intellinosis is a diagnostic company that focuses on developing molecular diagnostic reagents. Intellinosis is headquartered in Minhang District, China.

CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Ailomics Therapeutics, founded in 2022 and headquartered in Shanghai, China, is dedicated to developing innovative drugs for the treatment of immune diseases and tumors. The company utilizes a computational biology platform to analyze multi-omics data from patients, which aids in discovering novel drug mechanisms and targets that contribute to disease progression. Through this approach, Ailomics aims to enhance the understanding of complex diseases and advance the development of effective therapeutic solutions.

OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.

Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.

Resunbio provides micro-nano processing research and development precipitation. Resunbio is headquartered in Longhua, China.

RiboX Therapeutics is a biotech company that focuses on discovery and development of fully engineered circular RNA therapeutics.

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.

Ashermed is a provider of contract research organization (CRO) services tailored for medical companies. The company emphasizes the integration of advanced technologies, including Internet technology, big data, and artificial intelligence, into its offerings. By doing so, Ashermed aims to help medical companies shorten the drug development cycle, enhance the quality of clinical data, and lower research and development costs. Their services encompass CRO, site management organization (SMO), patient recruitment, and digital platform support, positioning them as a comprehensive partner in the medical research industry.

Wanzhong Yixin Biotechnology is a developer of semiconductor integrated circuit biosensor chips and other related devices. The company's biosensor chip products are used in emerging fields such as genetic testing, water quality monitoring, and environmental protection IoT monitoring.

LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.

Curie.Bio, founded in 2022 and based in Boston, Massachusetts, is a venture capital firm that specializes in seed-stage investments. The firm focuses on early-stage therapeutics companies, aiming to support innovative solutions in the life sciences sector. As a Registered Investment Adviser, Curie.Bio is dedicated to fostering growth and development in the biotechnology field by partnering with founders and providing the necessary resources to help advance their ventures.

Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.

JIIOV Technology is a biometric recognition solutions provider.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.

Zhenge Biotech is a macromolecular pharmaceutical contract development and manufacturing organisation.

Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

DP Technology is a global leader in the "AI for Science" research paradigm, where AI learns scientific principles and data, then tackles key challenges in scientific research and industrial R&D. DP's commitment to interdisciplinary research has led to the creation of the DP "Particle Universe", an array of pre-trained large science models designed to bridge foundational research with practical industrial applications. DP's software suite includes the Bohrium® Scientific Research Space, Hermite® Computational Drug Design Platform, RiDYMO® Dynamics Platform, and Piloteye® Battery Design Automation Platform. Together, these platforms form a robust foundation for industrial innovation and an open ecosystem for AI in science, fostering advancements in key areas such as drug discovery, energy, material science, and information technology.

Sinogen Biopharma is founded with a vision to bridge China's biotech innovation to the US pharma market. The company licenses and develops innovative drugs from China.

Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics，pesticides，veterinary drugs, and new cosmetics.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical use. Founded in 2014, the company has developed a microfluidic bioreactor designed to generate functional platelets from human stem cell cultures at a commercial scale. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing a vital resource for patients worldwide. The company is also focused on advancing therapeutics within the fields of biotechnology and drug discovery.

Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.

Okeanos offers a custom synthesis and production of special chemical biological reagents and pharmaceutical intermediates for life sciences. The company's main products are modified nucleotides, unnatural amino acids, heterocycle, and fluorescent and labeling reagents. Okeanos offers chemical compounds, pharmaceutical intermediates to the world-famous pharmaceutical companies, such as Pfizer, P&G Novartis, etc and enjoys a good reputation from the customers.

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Genevide is a biotech company that specializes in gene research and development. Genevide was founded in 2019 and is located in Suzhou, Jiangsu, China.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Health Biotech is a research and development firm specializing in precision medicine through the application of mass spectrometry. The company focuses on early diagnosis, treatment, and monitoring of Alzheimer's disease, employing liquid chromatography-mass spectrometry techniques to quantitatively detect specific biomarkers associated with the condition. By offering comprehensive solutions that include tools, equipment, and reagent consumables, Health Biotech aims to provide reliable detection services for patients. Its innovative technology not only aids in identifying risks for Alzheimer's disease but also supports healthcare professionals in enhancing patient outcomes by delaying disease onset and improving cognitive abilities.